Literature DB >> 31868291

The Association between Whole-Brain MR Spectroscopy and IDH Mutation Status in Gliomas.

Mohammed Goryawala1, Efrat Saraf-Lavi1, Natalia Nagornaya1, Deborah Heros2, Ricardo Komotar3, Andrew A Maudsley1.   

Abstract

BACKGROUND AND
PURPOSE: Mutations in isocitrate dehydrogenase (IDH) have a direct effect on gliomagenesis. The purpose of this study is to quantify differences in brain metabolites due to IDH mutations.
METHODS: Magnetic Resonance Spectroscopic Imaging (MRSI) was performed in 35 patients with gliomas of different grade and varied IDH mutation status. Volumes of interest (VOIs) for active tumor (tVOI), peritumoral area (pVOI), and contralateral normal-appearing white matter (cVOI) were created. Metabolite ratios of Choline (Cho) to both N-acetylaspartate (NAA) and Creatine (Cr) were estimated. Ratios of Glutamate/Glutamine complex (Glx) and myoinositol (mIno) to Cr were also quantified. General linear models (GLMs) were used to estimate the effects of IDH mutation on metabolite measures, with age, gender, and tumor grade used as covariates.
RESULTS: GLM analysis showed that maximum Cho/NAA and Cho/Cr in the tVOI were significantly (P < .05) higher in IDH mutant lesions as compared to wild-type. In the pVOI, mean Cho/Cr was found to be significantly different among IDH mutant and wild-type gliomas. Mean Cho/NAA (P = .306) and Cho/Cr (P = .292) within the tVOI were not significantly different. Ratios of Glx/Cr and mIno/Cr in any region showed no significant differences between IDH mutant and wild-type gliomas. No significant differences in metabolite ratios were seen in the cVOI between IDH mutants and wild-types.
CONCLUSION: IDH mutation's effect in gliomas show an increase in Cho in the tumor and perilesional regions as compared to wild-type lesions but do not show widespread changes across the brain.
© 2019 by the American Society of Neuroimaging.

Entities:  

Keywords:  MRSI; choline; glioma; isocitrate dehydrogenase (IDH); mutation

Year:  2019        PMID: 31868291      PMCID: PMC7485119          DOI: 10.1111/jon.12685

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  33 in total

1.  Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging.

Authors:  A A Maudsley; A Darkazanli; J R Alger; L O Hall; N Schuff; C Studholme; Y Yu; A Ebel; A Frew; D Goldgof; Y Gu; R Pagare; F Rousseau; K Sivasankaran; B J Soher; P Weber; K Young; X Zhu
Journal:  NMR Biomed       Date:  2006-06       Impact factor: 4.044

2.  Regional distributions of brain glutamate and glutamine in normal subjects.

Authors:  Mohammed Z Goryawala; Sulaiman Sheriff; Andrew A Maudsley
Journal:  NMR Biomed       Date:  2016-06-28       Impact factor: 4.044

3.  Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.

Authors:  Tali Mazor; Charles Chesnelong; Aleksandr Pankov; Llewellyn E Jalbert; Chibo Hong; Josie Hayes; Ivan V Smirnov; Roxanne Marshall; Camila F Souza; Yaoqing Shen; Pavithra Viswanath; Houtan Noushmehr; Sabrina M Ronen; Steven J M Jones; Marco A Marra; J Gregory Cairncross; Arie Perry; Sarah J Nelson; Susan M Chang; Andrew W Bollen; Annette M Molinaro; Henrik Bengtsson; Adam B Olshen; Samuel Weiss; Joanna J Phillips; H Artee Luchman; Joseph F Costello
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-15       Impact factor: 11.205

4.  Value of diffusion kurtosis imaging in assessing low-grade gliomas.

Authors:  Mohammed Z Goryawala; Deborah O Heros; Ricardo J Komotar; Sulaiman Sheriff; Efrat Saraf-Lavi; Andrew A Maudsley
Journal:  J Magn Reson Imaging       Date:  2018-03-23       Impact factor: 4.813

5.  Association of metabolite concentrations and water diffusivity in normal appearing brain tissue with glioma grade.

Authors:  Andrew A Maudsley; Bhaswati Roy; Rakesh K Gupta; Sulaiman Sheriff; Rishi Awasthi; Meng Gu; Nuzhat Husain; Sudipa Mohakud; Sanjay Behari; Daniel M Spielman
Journal:  J Neuroimaging       Date:  2013-11-19       Impact factor: 2.486

6.  Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.

Authors:  Ovidiu C Andronesi; Grace S Kim; Elizabeth Gerstner; Tracy Batchelor; Aria A Tzika; Valeria R Fantin; Matthew G Vander Heiden; A Gregory Sorensen
Journal:  Sci Transl Med       Date:  2012-01-11       Impact factor: 17.956

7.  Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI).

Authors:  A A Maudsley; C Domenig; V Govind; A Darkazanli; C Studholme; K Arheart; C Bloomer
Journal:  Magn Reson Med       Date:  2009-03       Impact factor: 4.668

8.  Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

Authors:  Peppi Koivunen; Sungwoo Lee; Christopher G Duncan; Giselle Lopez; Gang Lu; Shakti Ramkissoon; Julie A Losman; Päivi Joensuu; Ulrich Bergmann; Stefan Gross; Jeremy Travins; Samuel Weiss; Ryan Looper; Keith L Ligon; Roel G W Verhaak; Hai Yan; William G Kaelin
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

Review 9.  IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Authors:  Chunzhi Zhang; Lynette M Moore; Xia Li; W K Alfred Yung; Wei Zhang
Journal:  Neuro Oncol       Date:  2013-07-21       Impact factor: 13.029

Review 10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Adam L Cohen; Sheri L Holmen; Howard Colman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 6.030

View more
  4 in total

1.  T1-weighted and T2-weighted Subtraction MR Images for Glioma Visualization and Grading.

Authors:  Mohammed Goryawala; Bhaswati Roy; Rakesh K Gupta; Andrew A Maudsley
Journal:  J Neuroimaging       Date:  2020-11-30       Impact factor: 2.324

Review 2.  Emerging MR Imaging and Spectroscopic Methods to Study Brain Tumor Metabolism.

Authors:  Manoj Kumar; Ravi Prakash Reddy Nanga; Gaurav Verma; Neil Wilson; Jean Christophe Brisset; Kavindra Nath; Sanjeev Chawla
Journal:  Front Neurol       Date:  2022-03-16       Impact factor: 4.003

3.  A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma.

Authors:  Karthik Ramesh; Eric A Mellon; Saumya S Gurbani; Brent D Weinberg; Eduard Schreibmann; Sulaiman A Sheriff; Mohammed Goryawala; Macarena de le Fuente; Bree R Eaton; Jim Zhong; Alfredo D Voloschin; Soma Sengupta; Erin M Dunbar; Matthias Holdhoff; Peter B Barker; Andrew A Maudsley; Lawrence R Kleinberg; Hyunsuk Shim; Hui-Kuo G Shu
Journal:  Neurooncol Adv       Date:  2022-01-27

Review 4.  Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile.

Authors:  Francesca Branzoli; Małgorzata Marjańska
Journal:  Curr Opin Neurol       Date:  2020-08       Impact factor: 6.283

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.